10.70
10.70 (0%)
As of Feb 14, 2025
Intellia Therapeutics Inc [NTLA]
Source:
Company Overview
Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | ( 857 ) 285-6200 |
| Industry | manufacturing |
| CEO | John M. Leonard, M.D. |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $57.9 |
| Operating Profit | $-534.3 |
| Net Income | $-519 |
| Net Cash | $-37.6 |
Profit Ratios
| Gross Margin | $57.9 |
| Operating Margin | -923.1 |
| Profit as % of Revenues | -11.2% |
| Profit as % of Assets | -41.7% |
| Profit as % of Stockholder Equity | -59.5% |
Management Effectiveness
| Return on Equity | -59.5% |
| Return on Assets | -43.6% |
| Turnover Ratio | 4.7% |
| EBITA | $-534.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,191 |
| Total Liabilities | $319.1 |
| Operating Cash Flow | $-348.9 |
| Investing Cash Flow | $125.6 |
| Financing Cash Flow | $185.7 |
